Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.
2.

Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: relationship between CK15+ progenitor/amplified cells and pre-malignant lesions and invasive disease.

Celis JE, Gromova I, Cabezón T, Gromov P, Shen T, Timmermans-Wielenga V, Rank F, Moreira JM.

Mol Oncol. 2007 Dec;1(3):321-49. doi: 10.1016/j.molonc.2007.09.004. Epub 2007 Sep 25.

3.

Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.

Khalifeh IM, Albarracin C, Diaz LK, Symmans FW, Edgerton ME, Hwang RF, Sneige N.

Am J Surg Pathol. 2008 Apr;32(4):544-52. doi: 10.1097/PAS.0b013e31815a87e2.

PMID:
18300793
4.

The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?

Fadare O, Wang SA, Hileeto D.

Hum Pathol. 2008 Mar;39(3):331-6. doi: 10.1016/j.humpath.2007.07.014.

PMID:
18261623
5.
6.

Basal cytokeratin expression in relation to immunohistochemical and clinical characterization in breast cancer patients with triple negative phenotype.

Liu ZB, Wu J, Ping B, Feng LQ, Di GH, Lu JS, Shen KW, Shen ZZ, Shaol ZM.

Tumori. 2009 Jan-Feb;95(1):53-62.

7.

Triple-negative breast carcinoma in women from Vietnam and the United States: characterization of differential marker expression by tissue microarray.

Williams DJ, Cohen C, To TV, Page AJ, Lawson D, Sussman ZM, Nassar A.

Hum Pathol. 2009 Aug;40(8):1176-81. doi: 10.1016/j.humpath.2009.01.003. Epub 2009 Apr 14.

PMID:
19368951
8.

Expression of basal and luminal cytokeratins in breast cancer and their correlation with clinicopathological prognostic variables.

Mohammadizadeh F, Naimi A, Rajabi P, Ghasemibasir H, Eftekhari A.

Indian J Med Sci. 2009 Apr;63(4):152-62. doi: 10.4103/0019-5359.50764.

9.

Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.

Pintens S, Neven P, Drijkoningen M, Van Belle V, Moerman P, Christiaens MR, Smeets A, Wildiers H, Vanden Bempt I.

J Clin Pathol. 2009 Jul;62(7):624-8. doi: 10.1136/jcp.2008.061358.

PMID:
19561231
10.

Relevance of the immunohistochemical expression of cytokeratin 8/18 for the diagnosis and classification of breast cancer.

Cîmpean AM, Suciu C, Ceauşu R, Tătucu D, Mureşan AM, Raica M.

Rom J Morphol Embryol. 2008;49(4):479-83.

11.

Expression of basal keratins and vimentin in breast cancers of young women correlates with adverse pathologic parameters.

Chen MH, Yip GW, Tse GM, Moriya T, Lui PC, Zin ML, Bay BH, Tan PH.

Mod Pathol. 2008 Oct;21(10):1183-91. doi: 10.1038/modpathol.2008.90. Epub 2008 Jun 6.

12.

Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum.

Laé M, Fréneaux P, Sastre-Garau X, Chouchane O, Sigal-Zafrani B, Vincent-Salomon A.

Mod Pathol. 2009 Feb;22(2):291-8. doi: 10.1038/modpathol.2008.184. Epub 2008 Nov 14.

13.
14.

Detection of circulating gastric cancer cells in peripheral blood using real time quantitative RT-PCR.

Koga T, Tokunaga E, Sumiyoshi Y, Oki E, Oda S, Takahashi I, Kakeji Y, Baba H, Maehara Y.

Hepatogastroenterology. 2008 May-Jun;55(84):1131-5.

PMID:
18705345
15.

[mRNA expression of CK19 and CEA in peripheral blood of patients with breast cancer detected by real-time quantitative PCR].

Zheng HY, Chen Q, Ye YB, Huang WW.

Zhonghua Yi Xue Za Zhi. 2008 Aug 19;88(32):2267-70. Chinese.

PMID:
19087676
16.

Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer.

Rexhepaj E, Brennan DJ, Holloway P, Kay EW, McCann AH, Landberg G, Duffy MJ, Jirstrom K, Gallagher WM.

Breast Cancer Res. 2008;10(5):R89. doi: 10.1186/bcr2187. Epub 2008 Oct 23.

17.

Immunohistochemical profiling of cytokeratin expression by endometrial stroma sarcoma.

Adegboyega PA, Qiu S.

Hum Pathol. 2008 Oct;39(10):1459-64. doi: 10.1016/j.humpath.2008.02.008. Epub 2008 Jul 11.

PMID:
18619644
18.

The role of immunohistochemistry in the differential diagnosis of breast lesions.

Moriya T, Kozuka Y, Kanomata N, Tse GM, Tan PH.

Pathology. 2009 Jan;41(1):68-76. doi: 10.1080/00313020802563544.

PMID:
19089742
19.

Cytokeratin 5 and estrogen receptor immunohistochemistry as a useful adjunct in identifying atypical papillary lesions on breast needle core biopsy.

Grin A, O'Malley FP, Mulligan AM.

Am J Surg Pathol. 2009 Nov;33(11):1615-23. doi: 10.1097/PAS.0b013e3181aec446.

PMID:
19675450
20.

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.

Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO.

Clin Cancer Res. 2008 Mar 1;14(5):1368-76. doi: 10.1158/1078-0432.CCR-07-1658.

Items per page

Supplemental Content

Write to the Help Desk